Circadian Variations in Ocular Blood Flow in Glaucomatous and Normal Eyes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2000-11-30

Study Completion Date

2001-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

After focusing many years only on intraocular pressure (IOP) as the primary risk factor, recently the impact of ocular blood flow is getting more consideration for the pathophysiology of glaucoma. The circadian change of intraocular pressure (IOP) is well investigated, but diurnal variations in ocular blood flow are yet to be evaluated, especially in glaucomatous eyes.

This study is performed to investigate circadian variation of ocular blood flow assessed by laser interferometric fundus pulsation amplitude (FPA) and laser Doppler flowmetry (LDF) in glaucomatous eyes during topical antiglaucoma therapy at 8:00, 12:00, 17:00 and 21:00, to compare these circadian variation of ocular blood flow in glaucomatous eyes with variations in healthy eyes and to relate blood flow variations with IOP variations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma, Open-Angle Circadian Rhythm Intraocular Pressure Regional Blood Flow

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Laser Doppler flowmetry Choroidal blood flow Fundus pulsation amplitude Intraocular Pressure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

15 patients with primary open angle glaucoma

No interventions assigned to this group

2

15 age matched healthy subjects

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For the glaucoma patients:

* Medical controlled Primary Open Angle Glaucoma with a history of more than 2 years
* Topical medication with beta-blockers (timolol, betaxolol, levobunol)
* IOP with medication \< 22 mmHg (with a medical history of IOP \> 22 mmHg)
* Visual field testing: mild glaucomatous defects (Humphrey 30-2 with MD\>10)
* Optic nerve head: C/D-ratio between 0.4 and 0.9
* ametropy \< 3 dpt
* Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant

For the age matched control subjects:

* Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
* Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant
* Normal ophthalmic findings, ametropy \< 3 dpt.

Exclusion Criteria

For the glaucoma patients:

* History of trabeculectomy or laser trabeculoplasty
* Any other ocular disease with possible vascular involvement such as diabetic retinopathy, age related macular disease, retinal vein or artery occlusion.
* Uncontrolled systemic hypertension (defined as systolic blood pressure \> 170 mmHg or diastolic blood pressure \> 100 mmHg)
* Diabetes mellitus

For the age matched control subjects:

* abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
* Symptoms of a clinically relevant illness in the 3 weeks before the first study day
* History or presence of gastrointestinal, liver or kidney disease
* Ametropy \> 3 dpt

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Medical University of Vienna

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Georgopoulos, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Clinical Ophthalmology, Medical University of Vienna

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Clinical Pharmacology, Medical University of Vienna

Vienna, , Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OPHT-171000

Identifier Type: -

Identifier Source: org_study_id